HYBIO(SZ:300199)2022-12-06 05:14Group 1: Product Overview - Terlipressin is a synthetic vasopressin analog initially developed in the early 1980s, primarily used for treating variceal bleeding due to liver cirrhosis [2] - It is widely applied in clinical settings for conditions such as hepatorenal syndrome, ascites due to cirrhosis, septic shock, burns, acute liver failure, and cardiac arrest [2] - Terlipressin is the only known drug that can improve survival rates in patients with liver cirrhosis-related complications, making it significant in treatment guidelines [2] Group 2: Market Position and Competition - The domestic market for injectable terlipressin is currently dominated by two companies: the original manufacturer, Ferring, and Hanyu Pharmaceutical [3] - Prior to 2009, the terlipressin market in China was monopolized by imported drugs until Hanyu launched its generic version, breaking the monopoly and filling a market gap [3] - Hanyu's terlipressin has shown rapid growth in sales, achieving a leading position in the domestic market [3] Group 3: Marketing Strategies - The marketing strategy for terlipressin combines academic promotion with expert education, focusing on various academic activities to enhance physician awareness [3] - The drug has gained recognition among experts, doctors, and patients due to its clinical efficacy and extensive market cultivation [3] - After being included in the national medical insurance directory, Hanyu plans to intensify academic and sales promotions to solidify and expand its competitive advantage in the market [3]